The alanine-serine-cysteine-transporter-2 (ASCT2 or SLC1A5) mediates the uptake of these glutamines into the cancer cells, and it has been noted that LC patients express these transporters with greater frequency [31]. The gene discussed is SLC1A5; the disease is laryngotracheoesophageal cleft.